Announcements

New York Academy of Sciences Immunology of Diabetes III

Editors: Carani B. Sanjeevi and Edwin Gale

The proceedings of the 7th IDS are now published as a volume of the Annals of the New York Academy of Sciences entitled 'Immunology of Diabetes III (volume 1037). The contents of this volume can be viewed at the following website: <http://www.annalsnyas.org/content/vol1037/issue1/>

To know more about the volume and the Immunology of the Diabetes Society, please visit: www.idsoc.org

16th International Symposium on the Autonomic Nervous System

Los Cabos, Mexico, 6-9 October, 2005

Deadlines for abstract submission are 16 May, 2005 for paper submission and 1 June, 2005 for online submission.

For further information:

Anita Zeller, AAS Executive Secretary,
American Autonomic Society,

18915 Inca Ave,

Lakeville, MN 55044,

Tel: +1-952-469-5837,

Fax: +1-952-469-8424,

E-mail: zeller.anita@mayo.edu,

Website: www.americanautonomicsociety.org.

The 7th International Symposium on VIP, PACAP and Related Peptides

Rouen, France, 11-14 September 2005

Contact:

Hubert Vaudry

Tel: +33-235-146624

Fax: +33-235-146946

E-mail: hubert.vaudry@univ-rouen.fr

Marc Laburthe

Tel: +33-144-856135

Fax: +33-142-288765

E-mail: laburthe@bichat.inserm.fr

For further information please visit the following site:
<http://www.vip-pacap2005.crihan.fr>

EASD News Section 5/2005

DOI 10.1007/S00125-005-1771-x

European Foundation for the Study of Diabetes (EFSD) and Eli Lilly and Company EFSD/Lilly European Diabetes Research Programme Request for Applications

The European Foundation for the Study of Diabetes and Eli Lilly announce up to Euro 1 Million in Additional Funds for Diabetes Research in Europe

Background

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the European Foundation for the Study of Diabetes (EFSD). The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Eli Lilly and Company is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Eli Lilly and Company is in Indianapolis, Indiana, USA.

Plan

EFSD and Eli Lilly and Company have established the EFSD/Lilly European Diabetes Research Fund to promote increased European diabetes research and to increase public awareness and political understanding of the magnitude and burden of the disease.

To achieve its goals and objectives the fund is issuing a request for applications (RFA) for research grants. The EFSD/Lilly Fund will accept applications within any area of basic or clinical diabetes research.

Funding

Up to Euro 1 million has been made available, over three years, for focused research grants. Research will

be performed in Europe and its associated countries. The grants will be distributed as follows:

- 2003 - Three grants, each of Euro 100,000
- 2004 - Four grants, each of Euro 100,000
- 2005 - Three grants, each of Euro 100,000

Mechanism of Support and Review

Research will be supported through the award of fixed sum grants, each of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000, payable in the first year and in one instalment. The Programme Board, at the suggestion of the Review Committee, may at its discretion recommend an award in a lesser amount considered more appropriate for the proposed studies.

Three awards will be granted annually over three years. A fourth award was additionally granted in 2004. Applications for an EFSD/Lilly Research Programme Fund Award are invited from single non-profit institutions or groups of affiliated institutions from Europe and associated countries. Applications will be subject to scientific review by a specialised and independent ad hoc committee. Funding will require approval by a joint EFSD and Lilly board convened for this purpose. Anticipated dates for application review and funding approval are given in the schedule at the end of this document.

Research Grant Applications

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review.

The deadlines for receipt of research grant applications are given in the schedule at the end of this document.

For the purpose of this programme, the budget of the research grants is limited to Euro 100,000 per annum. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under Budget Justification.

EFSD and Lilly reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.

Application forms may be requested from:
foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not acceptable and will not be sent to reviewers.

Applications should be submitted by 21 September 2005 (date of receipt in EFSD Office) to:

Viktor Jörgens, M.D., Executive Director
 European Foundation for the Study of Diabetes
 Rheindorfer Weg 3
 D-40591 Düsseldorf, Germany

Review Considerations

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on diabetes mellitus.

Reporting Requirements

All investigators funded by this programme are required to submit a scientific report at the end of the funding period. Investigators must provide EFSD with early notice of papers accepted for publication and must acknowledge the support of the Programme in such papers by use of the phrase: "This work was made possible by a grant from the EFSD/Lilly Research Fund".

Competitive Renewal

Applications for renewal of an EFSD/Lilly Research Fund Award will be accepted on a competitive basis, with the same review process as described in this announcement. Such applications will thus be considered in the same fashion as all other new applications received for review and without any special priority.

Schedule

Announcement: May 2005
Application Deadline: 21 September 2005
Anticipated Award: December 2005

Enquiries should be directed to:
Viktor Jörgens, M.D., Executive Director
European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf, Germany
Tel: +49-211-758469-0
Fax: +49-211-758469-29
e-mail: Foundation@easd.org